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identify the direct costs, including costs for drugs and medical services, and indi-
rect costs, including loss productivity, loss of work, cost for accommodation and 
transportation due to treatment and other costs of patient and caregivers. Results: 
Annual total cost per patient with asthma accounts for 6,618,682 VND, from which 
direct costs are 2.5 times more than indirect cost (4,738,682 vs 1,880,000 VND). The 
total cost of asthma has increased following the asthma severity with 4,960,278; 
8,098,156; 10,759,234; 13,196,280 VND in mild, intermittent, moderate and severe 
asthma rate. In the structure of total cost, following the asthma severity, the per-
centage of direct costs increases and indirect costs decreases especially in the mild 
rate. Total economic burden of asthma was 23,165 billion VND, from which 71.5% 
(16,585 billion VND) are for direct costs and 29.5% (6,580 billion VND) for indirect 
cost. ConClusions: The economic impact of asthma (23,165 billion VND) on asth-
matic patients, families and society is significant. According to the study, putting 
more public health efforts to better control asthma is the first necessary step to 
reduce the costs of asthma.
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objeCtives: The aim of this study is to assess health care expenditure by disease 
in order to provide detailed analyses of resource allocations for 2012, based on 
the French health care system database. Methods: Using information about 
60 millions of individuals from the general scheme insurance database (85% of 
the French population), we identified all people who received care for each of 56 
groups of diseases or medical events or treatments, which are frequent, severe 
and/or costly. Algorithms have been applied to each patient, using ICD-10 diag-
noses for long-term chronic diseases or hospital stays, specific drugs or medical 
procedures. Costs of all reimbursed expenditures (outpatient/inpatient care, dis-
ability/sickness benefits) were extracted per individual for a top-down method 
allocated expenditure to each of the 56 diseases based on the average expendi-
ture by disease calculated for individuals with only one disease. All expendi-
tures were thereafter extrapolated to the whole population to fit national health 
account aggregates. Results: Among the 146 billion euros of expenditures (all 
insurance schemes), 22.1 billion (15%) were related to psychiatric disorders and 
treatments, 14 (10%) to cancer, 14.6 (10%) to cardiovascular diseases, 7.5 (5%) to 
diabetes, 6.6 (5%) to vascular-risk treatments, 6.1 (4%) to neurologic disorders, 3.5 
(2%) to chronic respiratory diseases, 4.7 (3%) to inflammatory/rare diseases/HIV, 
3.5 (2%) to treated chronic renal insufficiency, 1.4 (1%) to liver/pancreas diseases, 
1.5 (1%) to chronic pain killer users and 4 (3%) to other long-term chronic diseases. 
Isolated hospitalizations represented 32.8 billion € (23%), basic care 14.6 (10%) and 
maternity 9.1 (6%). This analysis also provides detailed patterns of expenditures by 
diseases. ConClusions: Our study provides helpful information to policy mak-
ers by monitoring the performance of the health care system at a disease-based 
level. This tool will be used to forecast the impact of ageing and epidemiologic 
patterns on health expenditures.
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objeCtives: In 2010,3, 230 men were diagnosed with prostate cancer (PCa) in 
Ireland, yielding one of the highest incidence rates across Europe. The focus of this 
paper was to derive average costs for PCa diagnosis, treatment and follow-up, and 
to estimate the overall health care expenditure for PCa in 2010 in Ireland using 
a quasi, incidence-based, bottom-up approach. Methods: PCa (ICD10 C61) inci-
dence and treatment data during 2007-2010 was obtained from the National Cancer 
Registry Ireland. Estimates of resource use for items not recorded by the NCRI were 
sourced from the literature and expert opinion. Costs associated with detection, 
diagnosis, treatment, treatment complications, follow-up until year 4 post-diagnosis 
and terminal care were estimated using various sources including study-specific 
survey data, Irish hospital costs (HSE Casemix) and costs published in the literature. 
A payer’s perspective using direct costs was adopted and costs were reported in 
2010€ . Results: The overall expenditure associated with prostate specific antigen 
(PSA) testing for those diagnosed with PCa in 2010 was € 360,016 (average per patient 
cost (APPC) € 56 (confidence interval (CI): € 45, € 67)). Diagnosis including biopsies 
and staging was estimated at € 2,872,333 (APPC € 804 (CI: € 573, € 1,114)). Treatment 
costs (for the first year) varied considerably with active surveillance estimated at 
€ 423,106 (APPC € 655 (CI: € 520, € 814)), external beam radiation therapy (in particular 
intensity-modulated radiation therapy) estimated at € 8,872,037 (APPC € 6,867 (CI: 
€ 5,429, € 8,235) and radical prostatectomy estimated at € 3,549,864 (APPC € 7,327 (CI: 
€ 5,797, € 8,787). The total burden of health care expenditure associated with PCa in 
2010 was approximately € 46.9 million (CI: € 37.4m, € 56.6m). ConClusions: PCa 
expenditure is substantial and represents a sizeable proportion of the Irish health 
care budget (€ 11bn). PCa incidence has steadily increased since 1998 due to increas-
ing PSA testing; should trends continue expenditure will increase and this will have 
implications for resource allocation in Ireland.
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reported were also considered for costing and values were derived from Tables 
Simpro and CBHPM. Exchange rate used was 1.00USD = 2.20BRL. Results: A total 
of 233 patients with lung cancer were identified at the database from which 101 were 
eligible to the study. Fifteen different chemotherapy regimens were reported. The 
most common regimen was carboplatin with pemetrexed (29,7%), 20,8% received 
bevacizumab containing regimen and only 6% were in use of oral chemotherapy. 
About 87% of the patients received a total of 3 cycles of treatment. Costs per cycle of 
the schemes observed ranged from US$ 11.890,36 to US$ 1.712,95. Considering the 
number of cycles administered reported in the database, the average cost of manage-
ment for one patient with metastatic NSCLC in 1L is US$19.001,79. ConClusions: 
Treatment of 1L metastatic NSCLC represents a significant burden to the Brazilian 
private payers. The preferences of chemotherapy regimens may change in the fol-
lowing years due to the incorporation of oral chemotherapy in the list of mandatory 
coverage treatments and procedures.
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objeCtives: To assess the management and associated lifetime costs in 
uMM patients as from the diagnosis of unresectable metastatic disease until 
death. Methods: We performed a retrospective patient chart review to obtain 
data on medical consumption related to the management of uMM. A complete 
registry of all patients diagnosed with melanoma at UZA between 2007 and May 
2014 was compiled. Eligible for this retrospective chart review were patients with 
uMM with sufficient data available and who deceased before May 2014. Data on 
demographics, disease characteristics and management of uMM were collected. 
Direct costs were calculated by multiplying each item of resource use with its 
unit cost (2013, € ) using the Belgian public health care payer’s perspective (PHCP) 
and patient’s perspective. Average (bootstrap 95%CI) overall costs per patient 
were calculated. Results: 396 patients were registered. 44 eligible patients were 
included. 81.8% (n= 36) of patients were treated by systemic treatment (s) of which 
13.6% (n= 6) received up to 4 different treatment lines. 14 patients received “new 
drugs” (ipilimumab: 13; vemurafenib: 4) 48/145 (40%) hospitalizations were for 
treatment administration. Mean overall cost/patient was € 45,297 (bootstrap 95% 
CI: 33,905- 57,550), of which € 44,346 (95%CI: 33,098-56,584) was reimbursed. The 
PHCP cost was driven by systemic treatments costs (51% of cost). Mean PHCP cost 
was € 93,537 (95 % CI: 81,710-105,346) for patients treated with “new drugs”, € 26,564 
(95 % CI: 20,688-32,999) for patients treated with chemotherapy but no “new drugs” 
and € 7,394 (95 % CI: 5,490-9,472) for patients on best supportive care (BSC) only. 
Median overall survival was 6.1 months (9 months, 5.2 months, and 1 month for 
patients treated with “new drugs”, with chemotherapy only, and with BSC only, 
respectively). ConClusions: Management of uMM results in considerable costs 
for the PHCP, mainly driven by systemic treatment costs.
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objeCtives: Breast cancer or rather called mastocarcinoma, is a malignant growth of 
the mammary gland. With an incidence rate of 5.105 people in 2010, breast cancer is 
the most frequent cancer disease in Austria. Annually about 1.500 cases of death are 
registered, therefore breast cancer is the leading cause for death among women. As a 
result, enormous costs arise for the health care system. Hence, the aim of the analysis 
was to evaluate the cost and disease burden of breast cancer. Methods: A burden of 
disease study, which evaluates all kinds of disease burden, like costs, quality adjusted 
life years (QALYs) and disability adjusted life years (DALYs) lost, was conducted. This 
analysis had an incidence based approach and projects costs over a time horizon of 
one year. Data were collected via literature review, published list prices and hospital 
records. Costs from published sources were used from the societal perspective. The 
direct costs include hospital, treatment and physician consultation costs. Indirect 
costs cover patient care giver costs as well as work absenteeism. Results: Each 
breast cancer patient causes direct costs of 6,423.91 EUR and indirect costs of 37,511.87 
EUR. Due to the fact that not only costs are important for the health care systems, 
the mortality rate, QALYs and DALYs were identified. The mortality rate of breast 
cancer conducts 7.7 percent of all cancer deaths in Austria. Compared to the healthy 
population, a breast cancer patient has average utility decrements of 0.11. With 
regard to an incidence rate of 5.105 people in 2010, a breast cancer patient will lose 
0.03 DALYs within one year. ConClusions: The analysis showed that the treatment 
of new diagnosed breast cancer patients causes about 225.5 million EUR. Moreover 
patients had a lower QALY of 561,55 and a loss of 153,15 DALYs within one year.
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objeCtives: Nowadays, health care costs of asthma are under pressure in all coun-
tries due to high prevalence, incidence and the chronic nature of disease. Estimating 
the economic burden of asthma from patients’ perspective is necessary not only to 
understand the value and structure, but also the economic influence of asthma to 
whole society to propose and implement the relevant medical. This is also the aim 
of this study. Methods: A tree-decision model has been developed to estimate the 
value and structure of the economic burden of asthma in Vietnam. The economic 
burden of asthma has been evaluated based on cost of asthma, including direct 
and indirect costs. A cohort of 227 asthma patients was selected to be surveyed to 
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objeCtives: Encompassing a group of cancers originating from the upper aero-
digestive tract, head and neck cancers are ranked in the top ten for both inci-
dence and mortality among all malignancies globally. This study aimed to estimate 
trends in total secondary care costs associated with the treatment of head and 
neck cancers in England from 2006/2007 to 2010/2011. Methods: Data on inpa-
tient and outpatient activity associated with oropharyngeal, oral cavity and laryn-
geal cancer was extracted from the Hospital Episode Statistics (HES) database. 
After grouping inpatient episodes into spells, a single Healthcare Resource Group 
(HRG) was derived for each and then cross-referenced with the National Tariff 
2010/11 to estimate the associated cost. For specific types of therapy, including 
chemotherapy and radiotherapy, HRG definitions were cross-referenced with the 
National Reference Costs for the latest available year and inflated using the PCI 
index. Outpatient costs were estimated by grouping consultations by treatment 
speciality. Results: The total cost of treatment for all cancers over the entire 
period was estimated to be around £309 million, at 2011 prices. Inpatient care 
covered by bundled HRGs accounted for over 90% of this cost, at £280 million. Total 
costs due to oropharyngeal cancer were slightly higher than those estimated for 
laryngeal and oral cancer, costing £115 million (37.06%), £96 million (31.15%) and 
£98 million (31.79%) respectively. There was, generally, an increasing trend in the 
secondary care burden of all three cancers. Annual costs and patient numbers 
increased the most for oropharyngeal cancer, with annual inpatient costs increas-
ing from £16,576,046 in 2006/07 to £28,467,016 in 2010/11. ConClusions: This 
study indicates that there is a significant, and increasing, health and economic 
burden associated with head and neck cancers in England, highlighting the need 
for preventative programmes.
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objeCtives: During chemotherapy, a majority of patients experience treatment-
related adverse-events (TEAEs). However, the number of patients requiring treat-
ment and/or hospitalization (T&H) for managing TEAEs is significantly lower. The 
objective of this study was to evaluate economic burden of TEAEs in third line 
Metastatic Breast Cancer (MBC) patients. Methods: A post-hoc analysis was con-
ducted on Phase 3 clinical trial of eribulin vs. Treatment of Physician’s Choice (TPC) 
in MBC patients with two prior chemotherapy regimens including anthracycline and 
taxane. TPC included capecitabine, gemcitabine, vinorelbine, docetaxel and pacli-
taxel. Grade 3&4 TEAEs which were observed in ≥ 5% of patients were considered. 
Patients who required T&H for managing TEAEs were further studied. Duration and 
costs associated with T&H were obtained from a micro-costing study where UK-NHS 
tariffs for each cost unit were applied. TEAE clinical trial frequency data for each 
treatment were annualized prior to cost evaluation, based on treatment duration 
(113 days for eribulin and 68 days for TPC patients). Results: Only a small propor-
tion of patients who experienced TEAEs required T&H. The frequencies of TEAEs 
experienced vs. TEAEs that required T&H for most commonly observed TEAEs were 
as follows: neutropenia (Eribulin: 45.2% vs. 14.5%; TPC: 21.1% vs. 5.3%), leukopenia 
(Eribulin: 13.9% vs 4.2%; TPC: 5.7% vs. 1.6%), peripheral-neuropathy (Eribulin: 8.2% 
vs. 3.8%; TPC: 2.0% vs. 0.4%) and asthenia/fatigue (Eribulin: 8.8% vs. 1.6%; TPC: 10.1% 
vs. 2.0%). Monthly TEAEs requiring T&H rates were Eribulin: 19.83%, TPC: 23.67%. 
Average annual costs for management of TEAEs were £2,621 for eribulin vs. £2,740 
for TPC patients. ConClusions: Economic burden of toxicities in MBC patients 
may be lower than expected as very few TEAEs require T&H. This study may have 
led to omission of rare but costly AEs because of the patient selection criteria used. 
Using individual treatments as comparators instead of TPC may have brought addi-
tional clarity to the results. Further research is warranted to validate the findings.
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intRoduCtion: Lung cancer is a highly prevalent condition with non-small 
cell lung cancer (NSCLC) representing ~80%. Given its high prevalence and poor 
survival rates, it is important to understand costs associated with NSCLC treat-
ment. objeCtives: To carry out a study similar to the study by Ramsey (2008) in 
three European countries: France, Germany and UK. Methods: Three similar 
administrative databases were accessed: Hospital Episode Statistics (England), 
Gesundheitsforen Leipzig (Germany), French Hospital Discharge system (France), 
using ICD-9/10 codes and treatment/surgery algorithms to identify NSCLC patients. 
An incidence population of NSCLC patients was obtained using an index year (rang-
ing from 2007-2008), ensuring the absence of prior lung cancer (12-months). Data 
were extracted on treatment information, patient characteristics and disease stag-
ing. Average NSCLC treatments were estimated by age and severity. For England 
20,081 patients were identified, for France, 15,061, for Germany, 1,038. Results: 
In-patient length of stay was 8.9, 8.7 and 10.1 days for France, England, Germany 
respectively for the first year. Hospital in-patient costs in the first year amounted 
to € 11,667, € 11,363, € 5,985 for France, Germany and England respectively. In year 
two these were € 5,916 (France), € 6,568 (Germany) and € 1,156 (England). Hospital out-
patient costs were in year 1 and 2: € 2,313 - € 676 (France); € 1,925 - € 1,766 (Germany); 
€ 1,209 - € 834 (England). Medicine costs in year 1 and 2 amounted to: € 3,542 - € 321 
(France); € 4,488 - € 3,805 (Germany); € 8,593 yr1 only (England). Other costs reported 
objeCtives: To examine the economic burden and health care utilizations 
of patients diagnosed with pancreatic cancer in the U. S. veteran popula-
tion. Methods: A retrospective database analysis was performed using Veterans 
Health Administration Medical SAS data from 01OCT2007 through 30SEP2012. 
Patients diagnosed with pancreatic cancer were identified using International 
Classification of Disease 9thRevision Clinical Modification (ICD-9-CM) code 157. 
The first diagnosis date was defined as the index date. A group of patients with 
similar age, region, gender and index year but without a pancreatic cancer diag-
nosis were identified as the comparison group and matched by baseline Charlson 
Comorbidity Index scores. One year of continuous health plan enrollment was 
required before and after the index date for both groups. Study outcomes, includ-
ing health care costs and utilizations, were compared between pancreatic cancer 
and comparator groups using 1: 1 propensity score matching (PSM). Results: A 
total of 10,894 patients were identified for the pancreatic cancer and comparison 
cohorts. After applying a 1: 1 PSM, 3,671 patients were matched from each cohort, 
and the baseline characteristics were proportionate. Pancreatic cancer patients 
were more likely to have higher health care resource utilizations, including inpa-
tient admissions (38.03% vs. 2.18%, p< 0.0001), emergency room (ER) (30.67% vs. 
5.48%, p< 0.0001), physician office visits (98.39% vs. 57.91%, p< 0.0001) and pre-
scription fills (83.55% vs. 62.82%, p< 0.0001). Risk-adjusted health care costs were 
also higher for pancreatic cancer patients, including inpatient ($18,079 vs. $442, 
p< 0.0001), ER ($330 vs. $46, p< 0.0001), physician office ($5,600 vs. $1,106, p< 0.0001) 
and pharmacy costs ($2,244 vs. $321, p< 0.0001), resulting in higher total costs 
($26,503 vs. $1,977, p< 0.0001) relative to the comparator cohort. ConClusions: 
During a period of 12 months, VHA patients diagnosed with pancreatic cancer 
reported higher health care resource utilization and costs than their matched 
controls.
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objeCtives: To explore the resource use and costs for multiple myeloma (MM) 
in a systematic literature review. Methods: We searched MEDLINE, Embase, the 
Cochrane Library, and EconLit for English-language studies published from January 1, 
2003 to May 16, 2013 that evaluated resource use and costs related to MM, includ-
ing relapsed or relapsed and refractory MM (R/RRMM). These studies underwent 
data abstraction and qualitative synthesis. Results: Thirteen primary studies in 
the US (n= 5), UK (n= 1), US and UK (n= 1), The Netherlands (n= 2), France (n= 1), Italy 
(n= 1), Sweden (n= 1), and Switzerland (n= 1) met the inclusion criteria. Three studies 
were in newly-diagnosed MM patients, one in newly-diagnosed and previously-
treated patients, and nine in R/RRMM. The key cost drivers in R/RMM (as percentages 
of total costs) were medications (32% to 66%), hospitalisations (15% to 35%), and 
adverse events/complications/comorbidities (6% to 42%). Among treatment-related 
adverse events in MM, neutropenia was the main cost driver, accounting for at 
least two-thirds of total costs for managing such events, followed by thrombocyto-
penia, anaemia, and infections. In addition, metastatic bone disease significantly 
increased direct treatment costs (+$57,720 per patient; 2004 USD) and accounted 
for 17% (€ 6,937 per patient; 2002 € ) of total MM treatment costs. Also, patients with 
progressive disease incurred costs over three times those in patients without disease 
progression after initial treatment ($837 vs. $237 PPPM [2010 USD]). ConClusions: 
The primary drivers of MM management costs are medication, hospitalisations, and 
adverse events. Neutropenia, skeletal complications and progressive disease are also 
especially costly in MM. This evidence highlights the need for effective therapies 
with improved tolerability profiles that delay progression across a broad range of 
patients with and without comorbidities.
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objeCtives: The objective of this study was to assess the breadth and usefulness of 
information available in social media and patient-specific forums on indirect costs 
of a disease. Methods: Internet searches of general social media and patient-spe-
cific forums were performed to identify sources of information on the indirect costs 
of breast cancer and schizophrenia. Results: Searches of general social media sites 
mainly resulted in posts related to available treatments, health awareness cam-
paigns, non-patient opinions and news articles, as well as irrelevant, often malicious 
posts, such as direct insults to schizophrenic patients. Fewer, but lengthier, posts 
were identified on patient forums, which could be an effective way of identifying 
indirect costs of the diseases. Such costs include time spent off work by the patient 
and their caregivers, delays in restoring independence such as being able to drive, 
and non-medical items used by women on chemotherapy. Breast cancer appears to 
be better represented than schizophrenia, possibly because patients with mental 
health problems face social stigma and thus don’t communicate their struggle as 
openly. Topics of conversation across forums include adverse treatment events and 
their associated costs, as well as other costs incurred by the patients due to their 
deteriorating health and quality of life. ConClusions: This study looked at avail-
able information on the economic burden of breast cancer and schizophrenia on its 
patients and found that general social media appear to be less useful than patient 
forums. Depending on the disease being researched, different kinds of information 
become available and prove to be useful in drawing conclusions about the indirect 
costs of an illness. The breast cancer community appears to be better represented 
and more vocal about resource use associated with the disease or treatment than 
the schizophrenia community. The perspective of caregivers is less represented in 
breast cancer than schizophrenia.
